REsect is a retrospective analysis of the SIRFLOX study patient cohort. The extensive radiological database of SIRFLOX was evaluated by a panel of 14 HPB (Hepato-Pancreato-Biliary) surgeons from leading medical centres in Belgium, France, Germany, Italy, The Netherlands, Spain, the UK and the USA to compare potential liver resectability at baseline and follow-up.

The results of REsect were presented at the 12th International Congress of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA), May 2017.

Key Findings

REsect demonstrated that the addition of SIR-Spheres Y-90 resin microspheres to FOLFOX (± bev)-based chemotherapy significantly increased the proportion of patients determined to have resectable liver metastases compared with chemo alone (38.11% in the SIRT + chemotherapy arm vs. 28.95% in the chemotherapy alone arm; p<0.0001).

Study Overview

A team of hepatobiliary surgeons performed independent analyses of baseline and follow-up scans from 472 patients. Five surgeons assessed at random 100 patients and the analysis of the remaining scans was conducted in groups of 22–25 cases by three surgeons randomly selected from the nine other members of the panel. The reviewers were blinded to patient identifiers, visit (baseline or follow-up), treatment and clinical information, as well as to the other reviewers’ assessments. A patient was deemed resectable or unresectable by majority agreement (≥3 of 5 surgeons or ≥2 of 3 surgeons).

Patient characteristics

A total of 472 patients with similar baseline characteristics were evaluable (mFOLFOX n=228; mFOLFOX + SIRT n = 244).

Eligibility for Resection

REsect showed increased eligibility for liver resection following SIR-Spheres Y-90 resin microspheres.

bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)

Garlipp B et al.  E-AHPBA 2017; Abs. FP 15.08.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage